Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human (468) Apply Human filter Veterinary (8) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Summaries of opinion (16) Apply Summaries of opinion filter Orphan designations (256) Apply Orphan designations filter Referrals (4) Apply Referrals filter

Product number

Patient safety

Yes (1) Apply Yes filter

Authorisation status

Authorised (245) Apply Authorised filter Refused (19) Apply Refused filter Withdrawn (26) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Withdrawal type

Initial authorisation (52) Apply Initial authorisation filter Post-authorisation (5) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (12) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (86) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (1) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter W: decision granting a waiver in all age groups for all conditions or indications (17) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (28) Apply Yes filter

Compliance procedure number

Medicine type

Accelerated assessment Remove Accelerated assessment filter Biosimilar Remove Biosimilar filter Orphan medicine Remove Orphan medicine filter Additional monitoring (617) Apply Additional monitoring filter Conditional approval (93) Apply Conditional approval filter Exceptional circumstances (67) Apply Exceptional circumstances filter Generic (350) Apply Generic filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

477 results

Remove all filtersRemove all filters

Medicine Withdrawn applications Remove Withdrawn applications filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Direct healthcare professional communication Remove Direct healthcare professional communication filter

Medicine type Biosimilar Remove Biosimilar filter Accelerated assessment Remove Accelerated assessment filter Orphan medicine Remove Orphan medicine filter

Sort by

List item

Human medicine European public assessment report (EPAR): Gazyvaro (updated)

Obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 22/07/2014, , , Revision: 15, Withdrawn, Last updated: 04/10/2023
List item

Human medicine European public assessment report (EPAR): Zarzio (updated)

filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 06/02/2009, , Revision: 24, Authorised, Last updated: 04/10/2023
List item

Human medicine European public assessment report (EPAR): Filgrastim Hexal (updated)

filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 06/02/2009, , Revision: 23, Authorised, Last updated: 04/10/2023
List item

Human medicine European public assessment report (EPAR): Yesafili (updated)

aflibercept, Macular Edema; Retinal Vein Occlusion; Diabetic Retinopathy; Myopia, Degenerative; Diabetes Complications
Date of authorisation: 15/09/2023, , , Authorised, Last updated: 03/10/2023
List item

Human medicine European public assessment report (EPAR): Tevimbra (updated)

Tislelizumab, Esophageal Squamous Cell Carcinoma
Date of authorisation: 15/09/2023, , , Authorised, Last updated: 02/10/2023
List item

Human medicine European public assessment report (EPAR): Tyenne (updated)

tocilizumab, Arthritis, Rheumatoid; Cytokine Release Syndrome; Arthritis, Juvenile Rheumatoid; COVID-19 virus infection; Giant Cell Arteritis
Date of authorisation: 15/09/2023, , Authorised, Last updated: 02/10/2023
List item

Human medicine European public assessment report (EPAR): SomaKit TOC (updated)

edotreotide, Neuroendocrine Tumors; Radionuclide Imaging
Date of authorisation: 08/12/2016, , Revision: 15, Authorised, Last updated: 29/09/2023
List item

Human medicine European public assessment report (EPAR): Hepcludex (updated)

Bulevirtide acetate, Hepatitis D, Chronic
Date of authorisation: 31/07/2020, , , Revision: 11, Authorised, Last updated: 28/09/2023
List item

Human medicine European public assessment report (EPAR): Tyruko (updated)

natalizumab, Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis
Date of authorisation: 22/09/2023, , , Authorised, Last updated: 28/09/2023
List item

Human medicine European public assessment report (EPAR): Kirsty (previously Kixelle) (updated)

insulin aspart, Diabetes Mellitus
Date of authorisation: 05/02/2021, , , Revision: 3, Authorised, Last updated: 27/09/2023
List item

Human medicine European public assessment report (EPAR): Trepulmix (updated)

Treprostinil sodium, Hypertension, Pulmonary
Date of authorisation: 03/04/2020, , Revision: 4, Authorised, Last updated: 27/09/2023
List item

Human medicine European public assessment report (EPAR): Sovaldi (updated)

Sofosbuvir, Hepatitis C, Chronic
Date of authorisation: 16/01/2014, , Revision: 28, Authorised, Last updated: 27/09/2023
List item

Human medicine European public assessment report (EPAR): Harvoni (updated)

ledipasvir, Sofosbuvir, Hepatitis C, Chronic
Date of authorisation: 17/11/2014, , Revision: 28, Authorised, Last updated: 27/09/2023
List item

Human medicine European public assessment report (EPAR): Epclusa (updated)

Sofosbuvir, velpatasvir, Hepatitis C, Chronic
Date of authorisation: 06/07/2016, , Revision: 22, Authorised, Last updated: 27/09/2023
List item

Human medicine European public assessment report (EPAR): Abrysvo (updated)

Respiratory syncytial virus, subgroup A, stabilized prefusion F protein / Respiratory syncytial virus, subgroup B, stabilized prefusion F protein, Respiratory Syncytial Virus Infections
Date of authorisation: 23/08/2023, , , Authorised, Last updated: 26/09/2023
List item

Human medicine European public assessment report (EPAR): Hyftor (updated)

Sirolimus, Angiofibroma; Tuberous Sclerosis
Date of authorisation: 15/05/2023, , Revision: 2, Authorised, Last updated: 25/09/2023
List item

Human medicine European public assessment report (EPAR): Amglidia (updated)

glibenclamide, Diabetes Mellitus
Date of authorisation: 24/05/2018, , Revision: 7, Authorised, Last updated: 25/09/2023
List item

Human medicine European public assessment report (EPAR): Evrysdi (updated)

Risdiplam, Muscular Atrophy, Spinal
Date of authorisation: 26/03/2021, , Revision: 5, Authorised, Last updated: 22/09/2023
List item

Human medicine European public assessment report (EPAR): Vyndaqel (updated)

tafamidis, Amyloidosis
Date of authorisation: 16/11/2011, , , , Revision: 27, Authorised, Last updated: 22/09/2023
List item

Human medicine European public assessment report (EPAR): Scemblix (updated)

asciminib hydrochloride, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation: 25/08/2022, , , Revision: 3, Authorised, Last updated: 22/09/2023
List item

Human medicine European public assessment report (EPAR): Lutathera (updated)

lutetium (177Lu) oxodotreotide, Neuroendocrine Tumors
Date of authorisation: 26/09/2017, , Revision: 10, Authorised, Last updated: 22/09/2023
List item

Human medicine European public assessment report (EPAR): Semglee (updated)

insulin glargine, Diabetes Mellitus
Date of authorisation: 23/03/2018, , Revision: 9, Authorised, Last updated: 22/09/2023
List item

Human medicine European public assessment report (EPAR): Talvey (updated)

talquetamab, Multiple Myeloma
Date of authorisation: 21/08/2023, , , , Authorised, Last updated: 21/09/2023
List item

Human medicine European public assessment report (EPAR): Herzuma (updated)

trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 09/02/2018, , Revision: 20, Authorised, Last updated: 20/09/2023
List item

Human medicine European public assessment report (EPAR): Hefiya (updated)

adalimumab, Spondylitis, Ankylosing; Hidradenitis Suppurativa; Psoriasis; Arthritis, Juvenile Rheumatoid; Uveitis
Date of authorisation: 26/07/2018, , Revision: 14, Authorised, Last updated: 20/09/2023